Navigation Links
Neurochem announces departure of Dr. Philippe Calais, President, Global Business
Date:11/30/2007

LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announces the departure of Philippe Calais, PhD. Pharm., Neurochem's President, Global Business. Dr. Calais joined Neurochem in 2003, and is leaving effective December 31, 2007, to pursue other interests.

"Dr. Calais has made a significant contribution to creating constructive relationships for Neurochem in international markets and we are grateful for having had the benefit of his expertise during the five years he has been with us," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. "We wish him every success in his new pursuits."

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to patients suffering from serious diseases.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit the Web Site at: http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data a
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ising incidence of obesity could counter recent in... 2 (HealthDay News) -- The overall health of the U...cades, largely because people have quit smoking in...t soon be wiped out if the rising obesity rates am...rent trends in both smoking and obesity continue u...
(Date:12/2/2009)...hes now available, many more to come, NIH director... News) -- Thirteen stem cell lines have been adde...-funded research, and many more such lines will so...ced Wednesday. , These are the first additional...unded by the U.S. National Institutes of Health (N...
(Date:12/2/2009)...WHITE PLAINS, N.Y., Dec. 2 /PRNewswire-USNewswire/... their findings in blood cancer research at the an...ce in New Orleans December 4-8, 2009. ,, Throu...oma Society (LLS) experts, including Chief Medical...esident of Patient Services Hildy Dillon, and Vice...
(Date:12/2/2009)...PHILADELPHIA, Dec. 2 Independence ...nefits contract with Lincoln Financial Group. IBC ...or approximately 10,000 Lincoln Financial Group em... nation. The Lincoln plan offerings will include t...s. ,, "I know I speak for all of us at Independ...
(Date:12/2/2009)...Joseph Balboni loves sports. An avid tennis player...old insurance agent became increasingly frustrated...us, a degenerative eye disorder. Unable to return ... he faced the prospect of a corneal transplant to ... years ago, Balboni discovered an alternative trea...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Brandeis studies evaluate visionary approach to improving eyesight 2
... Infections during the first year of life are a ma...s of arthritis later in life, according to new res...he Annual Congress of the European League Against ...irst birthday had an increased likelihood of devel...
...he issue of selling kidneys. , A regulated system...tion to the growing shortage of kidneys for transp...ry at the University of Minnesota. , In many are...is the annual death rate for suitable transplant c...
...pedics, Inc., a,leader in orthopedic extremity imp...ecutives, William F. Warrender, Jr., John F. Walte...s. Their extensive background and,experience will ...les. He brings more than 25 years of sales, market...
...Certain single nucleotide polymorphisms (SNPs) wit...region are shown to be associated with juvenile id... of two independent cohorts presented today at EUL... genetic code), rs2104286, rs41295061 and rs115946...
... WASHINGTON, June 13 A team of professionals,fro...to Germany on Saturday,to work with the US Army,s ...ng their current rehabilitation practices. They wi...tation,services. The ERMC operates 15 ambulatory c...
... try to resolve remaining issues, TORONTO, June 1...pany,PreMD Inc. (TSX: PMD; Amex: PME) today announ... the U.S. Food and Drug Administration (FDA) in an...next 60 days PreMD and the FDA will work together ...
Other Medicine News:Health News:Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis 2Health News:What's wrong with selling kidneys? 2Health News:Three Industry Veterans Join Ascension Orthopedics 2Health News:Three Industry Veterans Join Ascension Orthopedics 3Health News:Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:PreMD Reports Further Positive Meetings with the FDA 2
(Date:12/2/2009)..., , EAST HANOVER, N.J., Dec. 2 /PRNe... including a late-breaking presentation on Tasigna...ronic myeloid leukemia, demonstrate the strength o...the care of patients. ,, The new data, at the ...eeting and Exposition, highlight the company,s cur...
(Date:12/1/2009)..., , TEMECULA, Calif., Dec. 1 /PRNewswire-Fir...Bulletin Board: PSTX) announced today that it has ...f Chief Financial Officer, Treasurer and Corporate...ting CFO since 2008. Prior to joining Patient Saf...t Finance, Chief Financial Officer, Treasurer and ...
(Date:12/1/2009)..., , REDONDO BEACH, Calif., Dec. 1 /PRNewswire...ounces their Elective Single Embryo Transfer (eSET...entive for patients with good embryo quality and a...he chance of twins by transferring a single embryo... technology today is reducing the number of multip...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2GSK Advisory 3A Warehouse Theft 55192 1GSK Advisory 3A Warehouse Theft 55192 2American Lung Association in Minnesota 3A Motorists Can Get 85 Cents a Gallon E85 Fuel in Woodbury Minn 55189 1AMERIGROUP Corporation to Host Investor Day 55187 1
...ty of Hematology (ASH) and the American Society of... joint guideline on the use of,erythropoiesis-stim...late,the bone marrow to produce more red blood cel...oal of these guidelines is to inform clinicians wi...studies regarding the risks and,benefits of ESAs i...
...pplications for RNAi, WALTHAM, Mass., Oct. 22 Th...ld leader in serving science, has,collaborated wit...echnology,platform that expands applications for R...sciences research, including neuroscience, immunol...d Thermo Scientific Dharmacon(R),SMARTvector(TM) s...
Other Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research 2Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research 3
Shepard Bipolar Forceps Straight
Shepard Bipolar Forceps Angled
McCullough Bipolar Forceps
Dean Tonsil Knife
Medicine Products: